The data concerning the prevalence of genital and urinary tract infections in patients treated with SGLT2 inhibitors vary depending on several factors such as the type of the study carried out, the number of patients included, the inclusion/exclusion criteria, the follow-up period and, not least, additional factors that could precipitate such infections. Here, SLC5A2 is linked to urinary tract infection.